세계의 정량 분무식 흡입기 시장 규모는 2023년에 166억 1,300만 달러, 2030년까지 214억 2,300만 달러에 달하며, 2024-2030년의 예측 기간에 CAGR로 3.99%의 성장이 전망됩니다. 시장은 COVID-19의 유병률 증가, 당뇨병의 유병률 증가, 천식의 유병률 증가, 낭포성섬유증의 증례 급증, 만성폐쇄성폐질환(COPD)의 유병률 급증, 노년 인구의 증가, 제품의 제공에 관한 기술의 진보의 증가 등의 다양한 요인에 의해 플러스 성장을 보이고 있습니다. 따라서 정량 분무식 흡입기 시장은 2024-2030년의 예측 기간에 성장할 것으로 예측됩니다.
정량 분무식 흡입기 시장 역학
당뇨병 유병률 증가는 정량 분무식 흡입기 시장의 주요 촉진요인 중 하나입니다. 예를 들어 국제당뇨병연맹(IDF)이 2023년에 발표한 IDF Diabetes Atlas Tenth edition에 따르면 전 세계에서 20-79세 인구 중 약 5억 3,700만 명이 당뇨병을 앓고 있는 것으로 나타났습니다. 또한 당뇨병은 2030년까지 전 세계 6억 4,300만 명, 2045년까지 7억 8,300만 명이 앓고 있을 것으로 예측되고 있습니다. 또한 인슐린 분말은 당뇨병을 치료하기 위해 정량 분무식 흡입기를 통해 투여됩니다. 그 결과, 당뇨병 환자 증가는 정량 분무식 흡입기에 대한 수요를 증가시켜 예측 기간(2024-2030년) 동안 세계 정량 분무식 흡입기 시장을 촉진할 것으로 예상됩니다.
또 다른 주요 요인 중 하나는 천식 유병률 증가로 정량 분무식 흡입기 시장의 성장을 이끄는 또 다른 주요 요인입니다. 예를 들어 세계보건기구(WHO)가 2023년에 발표한 자료에 따르면 2019년 전 세계에서 약 2억 6,200만 명이 천식을 앓고 있는 것으로 추정됩니다. 또한 미국 천식 및 알레르기 재단(Asthma and Allergy Foundation of America)이 2023년에 발표한 데이터에 따르면 2019년 미국에서는 약 2,500만 명이 천식을 앓고 있었습니다. 따라서 정량 분무식 흡입기가 천식 치료에 사용되고 있습니다. 따라서 천식 유병률 증가는 정량 분무식 흡입기에 대한 수요를 증가시켜 예측 기간(2024-2030년) 동안 정량 분무식 흡입기 시장 전체를 발전시킬 것입니다.
그러나 정량 분무형 흡입기에 대한 인식 부족과 기기와 관련된 심각한 부작용은 세계 정량 분무형 흡입기 시장의 성장을 저해할 수 있습니다.
COVID-19는 정량적 분무식 흡입기 시장에 긍정적인 영향을 미치고 있습니다. 이는 COVID-19가 폐에 미치는 심각한 영향 때문인데, COVID-19 후유증으로 호흡기 감염에 걸릴 가능성이 있는 것으로 추정되는 COVID-19 회복 환자에서 정량 분무식 흡입기에 대한 수요가 급증했습니다. 따라서 2024-2030년의 예측 기간 중 정량 분무형 흡입기 수요는 지속적으로 증가할 것으로 예상됩니다.
정량적 분무식 흡입기 시장 부문 분석
정량 분무형 흡입기 시장의 용도 중 만성폐쇄성폐질환(COPD)은 2023년 큰 매출을 창출할 것으로 예측됩니다. 정량적 분무식 흡입기는 천식 치료제를 에어로졸 형태로 폐에 공급하는 휴대가 간편하고 사용하기 쉬운 장비입니다. 이들은 프로벤트 하이드로플루오로알칸(HFA)을 포함한 스테로이드, 심비코트와 같은 스테로이드/기관지확장제 조합, 복합제 등 다양한 COPD 치료제와 함께 사용할 수 있습니다. 따라서 정량 분무형 흡입기와 관련된 이러한 장점은 정량 분무형 흡입기에 대한 수요를 증가시켜 전체 정량 분무형 흡입기 시장을 증가시킬 수 있습니다. 한편, 정량 분무식 흡입기 관련 제품의 출시 증가도 시장 성장을 가속할 것입니다.
2020년 10월, 다국적 제약사 자이더스 카딜라(Zydus Cadila)는 인도 만성폐쇄성폐질환(COPD) 환자들을 위해 인도 최초의 지속성 무스카린 길항제(LAMA)와 지속성 베타 작용제(LABA)를 결합한 가압 정량 분무형 흡입기(pMDI)인 Forglyn pMDI의 출시를 발표했습니다.
세계의 정량 분무식 흡입기 시장에 대해 조사분석했으며, 시장 규모와 예측, 촉진요인과 과제, 기업과 제품 개요 등을 제공하고 있습니다.
Metered Dose Inhaler Devices Market By Patient Type (Adult And Pedriatric), By Application (Chronic Obstructive Pulmonary Diseases (Copd), Asthma, Covid-19, Diabetes, And Others), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of chronic obstructive pulmonary diseases (copd) and rising prevalence in asthma
The global metered dose inhaler devices market was valued at USD 16,613 million in 2023, growing at a CAGR of 3.99% during the forecast period from 2024 to 2030 to reach USD 21,423 million by 2030. The metered dose inhaler devices market is witnessing a positive growth owing to the various factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings. Therefore, the market for metered dose inhaler devices is estimated to grow during the forecast period from 2024 to 2030.
Metered Dose Inhaler Devices Market Dynamics:
The increased prevalence of diabetes is one of the key factors driving the market for metered dose inhaler devices. For instance, according to the International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth edition released in the year 2023, worldwide, diabetes had affected about 537 million people of age between 20-79 years. Moreover, diabetes can be predicted to affect 643 million people worldwide by 2030 and 783 million people by 2045. Further, insulin powder is administered by metered dose inhalers to treat diabetes. As a result, the demand for metered dose inhaler devices rises due to an increase in diabetes cases, propelling the global metered dose inhaler devices market ahead over the forecast period (2024-2030).
Moreover, another key factor which is responsible for the growth of metered dose inhaler devices market is the increasing prevalence of asthma. For instance, according to the data published by World Health Organization (WHO) in the year 2023, in 2019, asthma afflicted an estimated 262 million individuals globally. Moreover, as per the data published by Asthma and Allergy Foundation of America in the year 2023, in 2019, approximately 25 million people had asthma in the United States. Thus, metered dose inhaler devices are used to treat asthma. Therefore, rising prevalence in asthma increases the demand for metered dose inhaler devices, which drives the overall metered dose inhaler devices market forward over the forecast period (2024-2030).
However, lack of awareness about metered dose inhaler devices and severe side effects associated with the devices, can hamper the global metered dose inhaler devices market growth.
The COVID-19 pandemic has positively impacted the market for metered dose inhaler devices, this can be due to the severe effects of COVID on lungs and it is estimated that people may have respiratory infections as an after effect of COVID, which surged the demand for metered dose inhaler devices among patients recovering with COVID, as well as shortness of breath as its prevalent symptom also contributed to the metered dose inhaler devices demand among COVID patients. Hence, the demand for metered dose inhaler devices will continue to rise in the forecast period from 2024-2030.
Metered Dose Inhaler Devices Market Segment Analysis:
Metered dose inhaler devices market by Patient Type (Adult and Pediatric), Application (Chronic Obstructive Pulmonary Diseases (COPD), Asthma, COVID-19, Diabetes, and Others), Distribution Channel (Online and Offline), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In by application segment of metered dose inhaler devices market, Chronic Obstructive Pulmonary Diseases (COPD) are expected to share a significant revenue in the year 2023. Metered dose inhaler devices are a portable, easy-to-use device that delivers asthma medicine in aerosol form to the lungs. They may be used with a variety of COPD drugs, such as steroids including flovent hydrofluoroalkane (HFA) and a combination of steroid/bronchodilators such as Symbicort, and combination medications. Thus, these benefits associated with the metered dose inhaler devices can increase the demand of metered dose inhaler devices, which could increase the metered dose inhaler devices overall market. However, a rise in product launch associated with the metered dose inhaler devices also drives its market growth.
In October 2020, Zydus Cadila, multinational pharmaceutical company, announced the launch of Forglyn pMDI, India's first pressurized Metered Dose Inhaler (pMDI) with a combination of Long Acting Muscarinic Antagonist (LAMA) and Long Acting Beta Agonist (LABA) for patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in India.
Moreover, due to the interplay of all the factors mentioned above, results in the rising demand for metered dose inhaler devices, which in turn provide a conducive growth environment for overall metered dose inhaler devices during the market forecast of 2024-2030.
North America is expected to dominate the overall Metered Dose Inhaler Devices Market:
Among all the regions, North America is expected to dominate the global metered dose inhaler devices market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the rising prevalence of asthma and surge in cystic fibrosis cases are expected to increase the demand for metered dose inhaler devices in the North American market.
According to the data published by WHO from 3 January 2020 to 21 September 2022, there have been 94,471,064 confirmed cases of COVID-19 in United States. Further, COVID-19 increases the risk of respiratory infections in the patients affecting the lungs. Thus, rising prevalence of COVID increases the demand for metered dose inhaler devices, which surges the growth for metered dose inhaler devices overall market forecast.
Moreover, as per the latest data released by American Lung Association in the year 2020, cystic fibrosis affected approximately 30,000 people in the United States. Also, as per the cystic fibrosis Canada's 2020 annual data report from the Canadian Cystic Fibrosis Registry, released that in 2020, there were 4,332 Canadians with CF, with 62% of them being adults. Further, metered dose inhalers are available for the treatment of cystic fibrosis. Therefore, surge in cystic fibrosis cases would increase the demand for metered dose inhaler devices, which boost the metered dose inhaler devices overall market growth.
Furthermore, the factors mentioned above, provide a conducive growth environment for North American region in metered dose inhaler devices market.
Metered Dose Inhaler Devices Market Key Players:
Some of the key market players operating in the metered dose inhaler devices market include H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others.
Recent Developmental Activities in the Dry Powder Inhaler Devices:
In March 2022, Novartis' Sandoz, a Swiss multinational pharmaceutical corporation, acquired, UK based delivery device development company, Coalesce Product Development Limited, developing a portfolio of inhalation devices. This includes new versions of pressurized metered dose inhalers (pMDI), breath-actuated inhalers (BAI) and pre-metered dry powder inhalers (DPI).
In February 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced the launch of HeroTracker® Sense, a unique digital respiratory health solution that turns a normal metered dosage inhaler (pMDI) into a smart linked healthcare device.
In September 2022, BreatheSuite Inc., a Canadian connected respiratory health startup, announced that its BreatheSuite Metered-Dose Inhaler (MDI) V1 device has acquired 510(K) approval from the US Food and Drug Administration (FDA). The BreatheSuite gadget converts conventional MDIs into smart inhalers by automatically and objectively monitoring and delivering feedback on inhaler adherence and technique for persons with asthma and COPD. It is approved for both prescription and over-the-counter usage.
Key Takeaways from the Metered Dose Inhaler Devices Market Report Study
Target Audience who can be benefited from this Metered Dose Inhaler Devices Market Report Study
Frequently Asked Questions for Metered Dose Inhaler Devices:
The Metered Dose Inhaler device (MDI) is a medication canister that is pressurised and held in a plastic container with a mouthpiece. When sprayed, it delivers a constant and predictable amount of medicine. It is the most widely utilized delivery method for treating asthma, COPD, and other respiratory illnesses.
The global metered dose inhaler devices market was valued at USD 16,613 million in 2023, growing at a CAGR of 3.99% during the forecast period from 2024 to 2030 to reach USD 21,423 million by 2030.
The metered dose inhaler devices market is witnessing a positive market growth owing to the factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings.
Some of the key market players operating in the metered dose inhaler devices market include H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others.
North America is expected to dominate the global metered dose inhaler devices market. Factors contributing to the growth of metered dose inhaler devices market in the North America region are rising prevalence of COVID-19 and surge in cystic fibrosis cases.